Micro-stent is safe and effective after 2-years

Article

A supracilliary micro-stent, when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma, according to researchers in Germany and the US.

A supracilliary micro-stent (CyPass, Transcend Medical, Menlo Park, California, USA), when implanted in conjunction with cataract surgery, substantially reduces intraocular pressure (IOP) with minimal complications in patients with open-angle glaucoma (OAG), according to researchers in Germany and the US.

The researchers conducted a multicentre, prospective, consecutive case series of 136 eyes in 136 subjects with OAG. All of the eyes required cataract surgery, and underwent a combined phacoemulsification with intraocular lens insertion and implantation of the micro-stent. The researchers examined 24-month postoperative data.

At baseline, the subjects were divided into two cohorts: Cohort 1 (51 patients) had uncontrolled IOP of greater than 21 mmHg; Cohort 2 (85 patients) had controlled IOP of less than 21 mmHg. All of the patients were receiving glaucoma medications, which were discontinued postoperatively.

Eighty-two patients remained in the study through the 24-month follow up. After 24 months, the mean IOP in Cohort 1 (23 patients) was 15.8 ± 3.8 mmHg (a reduction of 37% ± 19%). The mean IOP decrease from baseline in Cohort 1 was statistically significant (P P = 0.0188) and 12 (P = 0.0356) in Cohort 2.

No sight-threatening adverse events occurred, and there was a statistically significant mean decrease of glaucoma medication use in both cohorts. To read an abstract of the study published in Klinische Monatsblätter für Augenheilkunde, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.